Press release: STADA brings in Berndt to further develop specialties and biosimilars offering
STADA brings in Berndt to further develop specialties and biosimilars offering
- Dr Christine Berndt joins STADA from June as Head of Global Development Specialties/Biosimilars
- Former Sandoz executive Berndt, who joins from MorphoSys, takes over from Dr Michael Mack, who is retiring after 18 years of service at STADA
- Bryan Kim, Head of Global Specialties, EVP: “Christine’s scientific expertise, combined with her extensive experience in product development and management consulting, will help us to build out our specialties offering to patients and healthcare professionals.”
Bad Vilbel, 22 April 2022 – STADA will from June add to its team by welcoming Dr Christine Berndt as Head of Global Development Specialties/Biosimilars. Former Sandoz executive Berndt, who joins from MorphoSys, takes over from Dr Michael Mack, who is retiring after 18 years of service at STADA.
Berndt, who will also hold the title of Vice-President, will be based at STADA’s headquarters in Bad Vilbel, Germany, and will report to Executive Vice-President and Head of Global Specialties, Bryan Kim. She will be responsible for the development strategy and execution of STADA’s growing specialties and biosimilars portfolio.
At MorphoSys, Berndt was Head of Global Program Strategy, Vice President, and a member of the German biopharmaceutical company’s Research and Development Leadership Team. In this role, she was responsible for building and leading the oncology specialist’s project management department in order to increase the organization's efficiency and efficacy. In addition, she was instrumental in boosting collaboration and decision-making across all development, commercial and technical functions, and served as the strategic representative for R&D in company-wide projects and initiatives.
Prior to MorphoSys, Berndt was a Global Program Head (GPH) for four biosimilar programs at Sandoz. In this position, she led multiple cross-functional teams across both development programs and in-market brands, managing biosimilars with immunology, endocrinology and oncology indications in regions including Europe and the US.
Holding a doctorate in cellular biology from the Universities of Barcelona and Hamburg, Berndt spent almost a decade with leading management consultancy Strategy&, formerly known as Booz Allen Hamilton. Her focus in this role lay on the life sciences and pharma sectors, spanning the entire pharmaceutical value chain for a multitude of global pharma and biotech companies.
“Christine’s scientific expertise, combined with her extensive experience in product development and management consulting, will help us to build out our specialties offering to patients and healthcare professionals,” stated Bryan Kim, STADA’s Head of Global Specialties. “With a comprehensive pipeline of biosimilars across therapeutic areas including oncology, immunology and ophthalmology, STADA represents an ideal choice for Christine to advance her career.”
“At STADA,” Kim continued, “Christine will be able to build on the robust platform created by her predecessor, Dr Michael Mack, who will retire at the end of June after 18 years of service to the group. Michael oversaw STADA’s entry into the biosimilars field since 2004 as a pioneer with the development of epoetin zeta, and he has seen STADA grow into a significant player in the field with subsequent launches of pegfilgrastim, teriparatide and bevacizumab.”
“I am delighted to be joining STADA in a role that will enable me to develop our biopharmaceutical growth story,” stated Berndt. “I am a strong believer in empowering the cross-functional teams I lead, and I look forward to contributing to greater patient access to competitive biological therapeutic options.”
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2021, STADA achieved group sales of EUR 3,249.5 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 776.5 million. As of 31 December 2021, STADA employed 12,520 people worldwide.
Additional information for journalists:
STADA Arzneimittel AG - Media Relations Stadastrasse 2-18 61118 Bad Vilbel - Germany Phone: +49 (0) 6101 603-165 Fax: +49 (0) 6101 603-215 E-Mail: firstname.lastname@example.org
Or visit us on the Internet at www.stada.com/press
Additional information for capital market participants:
STADA Arzneimittel AG - Investor & Creditor Relations Stadastrasse 2-18 61118 Bad Vilbel – Germany Phone: +49 (0) 6101 603-4689 Fax: +49 (0) 6101 603-215 E-mail: email@example.com
Or visit us on the Internet at www.stada.com/investor-relations